- South Korea president clings to power after martial law U-turn
- Presidential vote seen as referendum on Romania's European future
- Hamilton bids farewell to Mercedes as Ferrari vie for title
- New Zealand unchanged in bid to hit back against England
- Macron seeks remedy to France's political crisis
- New Natalia Lafourcade album celebrates music's onstage evolutions
- Taiwan's Lai kicks off visit to US territory Guam
- Ivory Coast staple cassava meal gains UNESCO heritage status
- OpenAI to partner with military defense tech company
- Liverpool held but Slot salutes 'special' Salah
- Man City needed to break losing 'routine', says Guardiola
- Leipzig down Frankfurt to reach German Cup quarters, Cologne strike late
- Mbappe admits penalty miss 'big mistake' as Bilbao beat Real Madrid
- 'Sad, disappointed' Mbappe pays penalty as Bilbao beat Real Madrid
- US stocks surge to records, shrugging off upheaval in South Korea, France
- Liverpool held in Newcastle thriller, Arsenal inflict Amorim's first defeat
- Shiffrin confirms she'll miss Beaver Creek World Cup races
- Corner kings Arsenal beat Man Utd to close gap on Liverpool
- Mbappe pays penalty as Bilbao beat Real Madrid
- NFL Jaguars place Lawrence on injured reserve with concussion
- North Korea, Russia defence treaty comes into force
- Openda hits brace as Leipzig beat Frankfurt in German Cup last 16
- Schar punishes Kelleher blunder as Newcastle hold Liverpool in thriller
- De Bruyne masterclass helps Man City end seven-game winless streak
- Syrian rebels surround Hama 'from three sides', monitor says
- Lawyers seek leniency for France rape trial defendants, blaming 'wolf' husband
- OpenAI chief 'believes' Musk will not abuse government power
- Thousands rally in Georgia after police raid opposition offices
- S. Korea opposition push to impeach president
- Powell 'not concerned' US Fed would lose independence under Trump
- French government falls in historic no-confidence vote
- Syrian White Helmets chief 'dreams' of never pulling a body out of rubble again
- NBA Suns lose Durant for at least a week with ankle injury
- Warhammer maker Games Workshop enters London's top stocks index
- Iran Nobel winner released for three weeks, 'unconditional' freedom urged
- Red Cross marks record numbers of humanitarians killed in 2024
- Johnson's Grand Slam 'no threat', says World Athletics boss Coe
- Qatar's emir and UK's Starmer talk trade as state visit ends
- Cuba suffers third nationwide blackout in two months
- Russia, Ukraine to send top diplomats to OSCE summit in Malta
- Spanish royals to attend memorial service for flood victims
- LPGA, USGA new policy requires female at birth or pre-puberty change
- Stick to current climate change laws, US tells top UN court
- British Museum chief says Marbles deal with Greece 'some distance' away
- Pope Francis receives electric popemobile from Mercedes
- Gaza civil defence: thousands flee Israeli strikes, evacuation calls
- Trump names billionaire private astronaut as next NASA chief
- Pidcock to leave INEOS Grenadiers at end of season
- Seoul stocks weaken, Paris advances despite political turmoil
- South America summit hopes to seal 'historic' trade deal with EU
Pfizer Covid pill preventing hospitalizations and deaths: White House
Pfizer's anti-Covid pill Paxlovid is helping stave off hospitalizations and deaths amid the United States' latest wave of infections, a senior White House official said Wednesday.
Demand for the treatment has soared, with a four-fold increase over the past month and an estimated 20,000 prescriptions being written every day, White House Covid-19 Response Coordinator Ashish Jha told reporters in a press call.
"I think that is actually a really important reason why, despite this very substantial increase in infections, we have not seen a commensurate increase in deaths," he said.
"We have seen hospitalizations rise, but again, not as much as one would have expected at this point, despite the fact that hospitalizations do lag. When you look at ICU care, the rate of ICU hospital admissions is much lower than what one would expect."
President Joe Biden's administration last month embarked on an aggressive push to expand access to the oral antiviral at tens of thousands of locations across the country.
Omicron's subvariants have driven daily new cases to 94,000, a three-fold increase over the last month, with hospitalizations running at 3,000 a day, and deaths at around 275.
Paxlovid, a combination of two drugs, both taken orally over five days, was shown in a clinical trial to reduce hospitalizations and deaths among at-risk people by almost 90 percent.
Concerns have been raised about "Paxlovid rebound" -- in which some patients clear the virus while on the treatment, but test positive after completing their course.
Jha said the government was studying the issue closely, "but I think it is not leading to people getting particularly sick." The rate of rebound during Paxlovid's clinical trial was two percent, but the dominant variant at the time was Delta.
He also encouraged doctors to adopt a "relatively permissive" approach to prescribing the medicine, given the broad eligibility criteria for being high risk.
"You should not get excessively restrictive, we have plenty of supply right now," he advised doctors.
Jha also urged Congress to quickly provide $22.5 billion in Covid funding so that the government could ensure the supply of next generation Covid vaccines, which are expected to protect against multiple variants.
"Other countries are in conversations with the manufacturers and starting to advance their negotiations," he said, warning Americans could be left behind.
If Congress failed to provide funding, "I think it'd be terrible, I think we'd see a lot of unnecessary loss of life if that were to happen," he said, but the Biden administration would try to find a way to provide vaccines to those at highest risk, he added.
M.Ouellet--BTB